ZA928647B - Novel hybrid transforming growth factors. - Google Patents

Novel hybrid transforming growth factors.

Info

Publication number
ZA928647B
ZA928647B ZA928647A ZA928647A ZA928647B ZA 928647 B ZA928647 B ZA 928647B ZA 928647 A ZA928647 A ZA 928647A ZA 928647 A ZA928647 A ZA 928647A ZA 928647 B ZA928647 B ZA 928647B
Authority
ZA
South Africa
Prior art keywords
growth factors
transforming growth
novel hybrid
hybrid transforming
novel
Prior art date
Application number
ZA928647A
Other languages
English (en)
Inventor
Gary Kent Mcmaster
David Cox
Nico Cerletti
Jochen Kuhla
Original Assignee
Ciba Geigy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy filed Critical Ciba Geigy
Publication of ZA928647B publication Critical patent/ZA928647B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ZA928647A 1991-11-11 1992-11-10 Novel hybrid transforming growth factors. ZA928647B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP91810870 1991-11-11

Publications (1)

Publication Number Publication Date
ZA928647B true ZA928647B (en) 1993-06-21

Family

ID=8208899

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA928647A ZA928647B (en) 1991-11-11 1992-11-10 Novel hybrid transforming growth factors.

Country Status (12)

Country Link
EP (1) EP0542679A1 (ja)
JP (1) JPH05306297A (ja)
KR (1) KR930010177A (ja)
AU (1) AU2738392A (ja)
CA (1) CA2082450A1 (ja)
FI (1) FI925086A (ja)
IL (1) IL103684A0 (ja)
MX (1) MX9206456A (ja)
NO (1) NO924323L (ja)
NZ (1) NZ245047A (ja)
TW (1) TW240231B (ja)
ZA (1) ZA928647B (ja)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8927546D0 (en) * 1989-12-06 1990-02-07 Ciba Geigy Process for the production of biologically active tgf-beta
US5436228A (en) * 1990-12-12 1995-07-25 Postlethwaite; Arnold E. Chemotactic wound healing peptides
US5824647A (en) * 1990-12-12 1998-10-20 Postlethwaite; Arnold E. Chemotactic wound healing peptides
GB9106678D0 (en) * 1991-03-28 1991-05-15 Ferguson Mark W J Wound healing
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6395494B1 (en) 1993-05-13 2002-05-28 Neorx Corporation Method to determine TGF-β
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
DE69435137D1 (de) * 1993-05-13 2008-10-16 Poniard Pharmaceuticals Inc Prävention und behandlung von pathologien, die mit einer abnormalen proliferationglatter muskelzellen verbunden sind
US6197789B1 (en) 1995-06-07 2001-03-06 Neorx Corporation Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
TW440566B (en) * 1994-07-25 2001-06-16 Novartis Ag Novel process for the production of biologically active dimeric protein
TW517059B (en) * 1994-07-25 2003-01-11 Ciba Geigy Ag New process for the production of biologically active protein
WO1998046588A2 (en) 1997-04-11 1998-10-22 Neorx Corporation Compounds and therapies for the prevention of vascular and non-vascular pathologies
ES2226414T3 (es) 1998-06-10 2005-03-16 Biognostik Gesellschaft Fur Biomolekulare Diagnostik Mbh Estimulacion del sistema inmunitario.
WO2002012336A2 (en) * 2000-08-09 2002-02-14 Curis, Inc. TGF-β THERAPEUTICS, COMPOSITIONS AND METHODS OF USE
JP2007531746A (ja) * 2004-04-02 2007-11-08 コーリー ファーマシューティカル グループ，インコーポレイテッド Ｉｌ−１０応答を誘導するための免疫活性化核酸
US9758786B2 (en) 2016-02-09 2017-09-12 Autotelic, Llc Compositions and methods for treating pancreatic cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ222168A (en) * 1986-10-20 1991-05-28 Oncogene Science Inc Tumour growth inhibiting protein related to tgf-#b#1 and tgf-#b#2, preparation by genetic engineering methods, antibodies and pharmaceutical compositions
US5221620A (en) * 1987-10-06 1993-06-22 Oncogen Cloning and expression of transforming growth factor β2
CA2005120A1 (en) * 1988-12-15 1990-06-15 Anthony F. Purchio Tgf-beta 1/beta 2: a novel chimeric transforming growth factor-beta
GB8927546D0 (en) * 1989-12-06 1990-02-07 Ciba Geigy Process for the production of biologically active tgf-beta

Also Published As

Publication number Publication date
NZ245047A (en) 1995-04-27
JPH05306297A (ja) 1993-11-19
NO924323L (no) 1993-05-12
MX9206456A (es) 1993-07-01
KR930010177A (ko) 1993-06-22
IL103684A0 (en) 1993-04-04
CA2082450A1 (en) 1993-05-12
FI925086A0 (fi) 1992-11-09
AU2738392A (en) 1993-05-13
EP0542679A1 (en) 1993-05-19
TW240231B (ja) 1995-02-11
NO924323D0 (no) 1992-11-10
FI925086A (fi) 1993-05-12

Similar Documents

Publication Publication Date Title
ZA917766B (en) Hybrid growth factors.
AU660321B2 (en) 1,2-dihydro-2-oxopyridine
EP0576870A3 (en) Culture device for microorganisms.
EP0679163A4 (en) FACTOR-3 OF GROWTH AND DIFFERENTIATION.
AU1398792A (en) Hybrid polypeptide
ZA928647B (en) Novel hybrid transforming growth factors.
EP0575559A4 (en) TGF-BETA1 / BETA2: CHIMERIC TRANSFORMING GROWTH FACTOR BETA.
AU1443592A (en) Object carrier
DE59204008D1 (en) Trachealstent.
ZA926482B (en) Cyanophenylpyrroles.
ZA927792B (en) Anti-alpha6-integrin-antibodies.
AU3921993A (en) Novel antler-derived bone growth factors
ZA929590B (en) Diphenylsulphides.
EP0565958A3 (de) Geteilte Webmaschine.
DE69205795D1 (en) Mesoprotheseunterlage.
ZA931481B (en) Implants.
EP0524791A3 (en) T-drive powertrain assembly
DE69203865D1 (en) Thermo-transferdrucksystem.
EP0586848A3 (de) Implantat.
ZA93781B (en) Novel antioxidants.
EP0575731A3 (en) Corona charger.
EP0528547A3 (en) T-drive powertrain assembly
DE69204801D1 (en) Hydroxy- oder oxosubstituierte alkylcyclopentene.
ZA929820B (en) Heisswinderschieber.
ZA929331B (en) Quinolylmethoxyphenyl-acetamides.